Indeed, IFN-β therapy modulates the expression of APC costimulatory molecules on PBMCs from MS patients [57] and downregulates dendritic cell and monocyte expression of IL-12 [32,58], the critical Th1 differentiation factor. Here, IFNB1 is linked to myeloid sarcoma.